Interstitial Cystitis
A chronic condition causing severe pelvic pain and a constant urge to urinate, without an active bacterial infection.
Emergency Management: Acute severe urinary retention secondary to painful pelvic floor muscle spasm requiring catheterization and antispasmodics.
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic condition characterized by pelvic or suprapubic pain, pressure, or discomfort perceived to be related to the urinary bladder, accompanied by urinary frequency and urgency, in the absence of infection or other identifiable pathology.
Detailed Overview
IC/BPS is a debilitating condition that severely impacts quality of life. The exact etiology is unknown but involves an altered bladder mucosal lining (defective glycosaminoglycan layer), neurogenic inflammation, and mast cell activation. Diagnosis is largely clinical after ruling out UTI, overactive bladder, and malignancy.
Epidemiology & Demographics
Prevalence is estimated at 3 to 8 million women and 1 to 4 million men in the US. Female-to-male ratio is roughly 5:1. Typical age of onset is over 40 years.
Etiological Mechanism
Unknown. Theories include urothelial dysfunction (leaky epithelium), autoimmunity, neurogenic inflammation, and occult infection.
Primary Causes
Epithelial dysfunction (loss of protective GAG layer)
Mast cell activation in bladder wall
Neurogenic upregulation/sensitization
Autoimmune response
The leading theory involves a defect in the protective glycosaminoglycan (GAG) layer of the urothelium. This 'leak' allows urinary solutes, notably potassium, to penetrate the submucosa and directly stimulate sensory C-fibers. This causes severe pain and triggers localized neurogenic inflammation, including mast cell degranulation (releasing histamine) and further mucosal injury. Over time, central sensitization of the nervous system leads to chronic neuropathic pain.
Diagnostic Criteria & Guidelines
Pelvic pain, pressure, or discomfort related to the bladder for at least 6 weeks, accompanied by at least one lower urinary tract symptom (urgency/frequency), in the absence of infection or other identifiable causes.
1. Behavioral modification and patient education. 2. Diet modification (avoiding triggers like coffee, alcohol, citrus). 3. Oral medications: Amitriptyline 10-25 mg PO QHS (titrated to 50 mg) or Pentosan polysulfate sodium (Elmiron) 100 mg PO TID. Antihistamines like Hydroxyzine 25-50 mg PO QHS.
Second-Line & Adjunctive Therapy
Intravesical instillation therapies: Dimethyl sulfoxide (DMSO), Heparin, or Lidocaine solutions instilled directly into the bladder via catheter. For Hunner's lesions: Cystoscopic fulguration (laser or electrocautery) or triamcinolone injection.
Surgical & Procedural Management
Sacral neuromodulation (InterStim) for refractory frequency. In end-stage disease with contracted bladder and intractable pain, cystectomy with urinary diversion (ileal conduit) is a last resort.
Patient Counseling & Advice
Set realistic expectations: there is no cure for IC/BPS, and treatment is focused on symptom control. Stress the importance of dietary triggers, as diet plays a massive role in flares.
Follow-Up & Monitoring Schedule
Regular follow-up to assess symptom scores (e.g., O'Leary-Sant Symptom Index). Patients on Pentosan polysulfate (Elmiron) require annual ophthalmologic exams due to the risk of pigmentary maculopathy.
Preventive Strategies
No known preventive measures, but recognizing and avoiding personal dietary triggers prevents acute flares.
Highly variable. Some patients experience spontaneous remission, while others have a chronic relapsing-remitting course requiring lifelong multimodal therapy.